METHOTREXATE SODIUM
| Brand name | XATMEP |
|---|---|
| Active ingredient | METHOTREXATE SODIUM |
| Strength | EQ 2.5MG BASE/ML |
| Dosage form | SOLUTION |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | April 2017 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 10231927 | January 2033 | use U-1349 |
| 11116724 | January 2033 | use U-1699 |
| 11969503 | January 2033 | product |
| 12396947 | January 2033 | product |
| 10610485 | January 2033 | product |
| 9855215 | January 2033 | product |
| 9259427 | January 2033 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.